JNCI-Journal of the National Cancer Institute

JNCI, the Journal of the National Cancer Institute, is a peer-reviewed oncology journal published by Oxford University Press, founded in 1940 and issuing twelve numbers a year in print and online, with a 2025 Journal Impact Factor of 7.7 and a rank of 49th among 333 oncology journals《美国国家癌症研究所杂志》（JNCI-Journal of the National Cancer Institute）是（Oxford University Press）出版的同行评审肿瘤学期刊，1940 年创刊，每年出版 12 期，印刷版与在线版并行，2025 年影响因子为 7.7，在 333 种肿瘤学期刊中列第 49 位。

Scope

• Clinical cancer research is the journal's centre of gravity, with emphasis on trials that change practice rather than on preclinical mechanism alone临床肿瘤研究是该刊的重心，强调能改变临床实践的试验，而非仅报告临床前机制。
• Epidemiology and cancer prevention are long-standing strengths, covering risk factors, screening and population-level intervention流行病学与癌症预防是长期强项，涵盖危险因素、筛查与人群层面的干预。
• Behavioural science and health outcomes research examine survivorship, adherence, communication and access to care行为科学与健康结局研究关注生存者管理、依从性、医患沟通与医疗可及性。
• Reviews, minireviews and commentaries are commissioned or accepted to place new findings in context for a broad oncology readership综述、短评与评论文章以约稿或投稿方式刊出，为广泛的肿瘤学读者提供新发现的位置与语境。
• Biostatistics and trial methodology are treated as substantive subjects, not merely as service sections生物统计与试验方法学被视为实质性主题，而非仅作为服务性栏目。
• Cancer control policy, including regulatory and economic questions that shape access to new agents, appears in the journal's news and commentary pages癌症防控政策，包括影响新药可及性的监管与经济问题，出现在该刊的新闻与评论版面。

History

• The journal was established in 1940 as the Journal of the National Cancer Institute, giving the United States a dedicated outlet for cancer research during the wartime expansion of federal science该刊 1940 年以《美国国家癌症研究所杂志》之名创刊，在联邦科学战时扩张的背景下为美国癌症研究提供了专属发表平台。
• Oxford University Press took over publication in 1996 and has since handled the title on a commercial basis（Oxford University Press）于 1996 年接手出版，此后以商业方式运营该刊。
• The journal is no longer affiliated with the National Cancer Institute, a point the publisher states explicitly to avoid confusion with the federal agency该刊现已与美国国家癌症研究所无隶属关系，出版方对此明确说明，以免与联邦机构混淆。
• A fully open access companion, JNCI Cancer Spectrum, was launched in 2017, and JNCI Monographs carries longer thematic collections2017 年创办全开放获取姊妹刊《JNCI 癌症谱》，另有《JNCI 专论》刊载篇幅较长的专题文集。
• Its impact factor was 13.506 in 2021, 11.816 in 2022, 7.2 in 2024 and 7.7 in 2025, and the median time from acceptance to publication is 22 days该刊影响因子 2021 年为 13.506，2022 年为 11.816，2024 年为 7.2，2025 年为 7.7；从录用到出版的中位时间为 22 天。

Editors

• The editor-in-chief is Eduardo L. Franco, a distinguished professor at McGill University in Montreal and a cancer epidemiologist known for work on human papillomavirus and cervical cancer现任主编为蒙特利尔麦吉尔大学（McGill University）杰出教授（Eduardo L. Franco），他是研究人乳头瘤病毒与宫颈癌的癌症流行病学家。
• An editorial board of senior oncologists and methodologists reviews submissions, and the journal advertises a rigorous yet rapid review process由资深肿瘤学家与方法学家组成的编委会负责审稿，该刊宣称其流程既严格又迅速。
• A structured early career investigator editorial mentorship programme gives trainees supervised peer review experience该刊设有结构化的青年研究者编辑导师计划，为受训者提供在指导下参与同行评审的机会。
• Accepted manuscripts are published online ahead of print and then assigned to one of the twelve monthly issues录用稿件先在线预发表，随后编入十二期月刊之一。
• The journal is a member of the Committee on Publication Ethics and applies its guidance on misconduct and correction该刊为出版伦理委员会（COPE）成员，并遵循其关于学术不端与更正的指引。